• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Euro Surveill. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and ant

Giuseppe

Emeritus
[Source: Eurosurveillance, full text: (LINK). Abstract, edited.]

Eurosurveillance, Volume 17, Issue 46, 15 November 2012

Research articles

The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use


P Zarb<SUP>1</SUP><SUP>,2</SUP>, B Coignard<SUP>3</SUP>, J Griskeviciene<SUP>4</SUP>, A Muller<SUP>2</SUP>, V Vankerckhoven<SUP>2</SUP>, K Weist<SUP>4</SUP>, M M Goossens<SUP>5</SUP>, S Vaerenberg<SUP>5</SUP>, S Hopkins<SUP>6</SUP>, B Catry<SUP>5</SUP>, D L Monnet<SUP>4</SUP>, H Goossens<SUP>2</SUP>, C Suetens ()<SUP>4</SUP>, National Contact Points for the ECDC pilot point prevalence survey<SUP>7</SUP>, Hospital Contact Points for the ECDC pilot point prevalence survey<SUP>7</SUP>
  1. Infection Control Unit, Mater Dei Hospital, Msida, Malta
  2. Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
  3. Institut de veille sanitaire, Saint-Maurice, France
  4. European Centre for Disease Prevention and Control, Stockholm, Sweden
  5. Scientific Institute of Public Health, Brussels, Belgium
  6. Health Protection Agency, London, United Kingdom
  7. The members of these groups are listed at the end of the article
<HR>
Citation style for this article: Zarb P, Coignard B, Griskeviciene J, Muller A, Vankerckhoven V, Weist K, Goossens MM, Vaerenberg S, Hopkins S, Catry B, Monnet DL, Goossens H, Suetens C, National Contact Points for the ECDC pilot point prevalence survey, Hospital Contact Points for the ECDC pilot point prevalence survey. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill. 2012;17(46):pii=20316. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20316
Date of submission: 15 May 2012
<HR>A standardised methodology for a combined point prevalence survey (PPS) on healthcare-associated infections (HAIs) and antimicrobial use in European acute care hospitals developed by the European Centre for Disease Prevention and Control was piloted across Europe. Variables were collected at national, hospital and patient level in 66 hospitals from 23 countries. A patient-based and a unit-based protocol were available. Feasibility was assessed via national and hospital questionnaires. Of 19,888 surveyed patients, 7.1% had an HAI and 34.6% were receiving at least one antimicrobial agent. Prevalence results were highest in intensive care units, with 28.1% patients with HAI, and 61.4% patients with antimicrobial use. Pneumonia and other lower respiratory tract infections (2.0% of patients; 95% confidence interval (CI): 1.8?2.2%) represented the most common type (25.7%) of HAI. Surgical prophylaxis was the indication for 17.3% of used antimicrobials and exceeded one day in 60.7% of cases. Risk factors in the patient-based protocol were provided for 98% or more of the included patients and all were independently associated with both presence of HAI and receiving an antimicrobial agent. The patient-based protocol required more work than the unit-based protocol, but allowed collecting detailed data and analysis of risk factors for HAI and antimicrobial use.
- ------
 
Back
Top Bottom